Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 19:12:1758835920925219.
doi: 10.1177/1758835920925219. eCollection 2020.

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

Emilio Francesco Giunta  1 , Vincenzo De Falco  1 , Stefania Napolitano  1 , Giuseppe Argenziano  2 , Gabriella Brancaccio  2 , Elvira Moscarella  2 , Davide Ciardiello  1 , Fortunato Ciardiello  1 , Teresa Troiani  3
Affiliations
Review

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

Emilio Francesco Giunta et al. Ther Adv Med Oncol. .

Abstract

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is still controversial. In fact, waiting for results of ongoing clinical trials and for new biomarkers, clinicians should base their decision on the clinical characteristics of the patient and on the biological aspects of the tumor. This review provides an overview on BRAF-V600 mutations in melanoma and will discuss their prognostic and clinical significance. Moreover, it will suggest a therapeutic algorithm that can drive therapeutic choice in a first-line setting for BRAF-V600 mutant melanoma patients.

Keywords: BRAF-V600 mutations; immunotherapy; metastatic melanoma; prognostic biomarker; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Teresa Troiani: Institutional research grants: Roche, Merck, Sanofi, Servier, Novartis, Bayer. Fortunato Ciardiello: Advisory boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene Lilly. Institutional research grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda. The remaining authors have no conflicts of interest to declare

Figures

Figure 1.
Figure 1.
Proposed algorithm for first-line treatment choice in untreated BRAF-V600 mutant metastatic melanoma patients. BRAFi, BRAF inhibitor; LDH, serum lactate dehydrogenase; MEKi, MEK inhibitor; SLD, sum of lesion diameters.
See this image and copyright information in PMC

References

    1. Matthews NH, Li WQ, Qureshi AA, et al. Epidemiology of melanoma – cutaneous melanoma: etiology and therapy [Internet]. Brisbane: Codon Publications, 2017. Chapter 1, 10.15586/codon.cutaneousmelanoma.2017.ch. - DOI
    1. American Cancer Society. Survival rates for melanoma skin cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-s... (accessed 18 February 2020).
    1. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1239–1251. - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535–1546. - PubMed
    1. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239–1246. - PubMed